Dispatches from Korea

Inside Celltrion: a biosimilar success story built on landfill

By Dan Stanton

29-Aug-2016 - Last updated on 30-Aug-2016 at 12:56 GMT

Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'

Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.

Biopharma-Reporter visited the 'pioneers of the mAb biosimilar industry'

Related news

Related products

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Learn more about KLEPTOSE® BioPharma for your protein stability challenges

Roquette Pharma Solutions | 14-Jun-2019 | Case Study

Therapeutic proteins are inherently unstable and sensitive to temperature change, shearing, shaking, solvents, ionic strength, purity, protein concentration,...

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...